SILO PHARMA INC (SILO) Stock News

NASDAQ:SILO - Nasdaq - US82711P2011 - Common Stock - Currency: USD

0.6293 +0.03 (+5.18%)

After market: 0.62 -0.01 (-1.48%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SILO Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Silo Pharma, Inc.

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

3 days ago - By: Silo Pharma, Inc.

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

23 days ago - By: Silo Pharma, Inc.

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

23 days ago - By: Silo Pharma, Inc.

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

a month ago - By: Silo Pharma, Inc.

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

a month ago - By: Silo Pharma, Inc.

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

a month ago - By: Silo Pharma, Inc.

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

a month ago - By: Silo Pharma, Inc. - Mentions: HOTH

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

a month ago - By: Hoth Therapeutics, Inc. - Mentions: HOTH

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty

2 months ago - By: Silo Pharma, Inc.

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

2 months ago - By: Silo Pharma, Inc.

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

2 months ago - By: Benzinga - Mentions: OMH ELAB GHM KLTO ...

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

2 months ago - By: Benzinga - Mentions: BLRX GLYC HSDT CLSD ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 months ago - By: Silo Pharma, Inc.

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

2 months ago - By: Silo Pharma, Inc.

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Announces Closing of $2 Million Public Offering

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Announces Closing of $2 Million Public Offering

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Announces Pricing of $2 Million Public Offering

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Announces Pricing of $2 Million Public Offering

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

3 months ago - By: Silo Pharma, Inc.

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories